LPT 99

Drug Profile

LPT 99

Alternative Names: LPT99

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Loop Therapeutics
  • Developer Spiral Therapeutics
  • Class Small molecules
  • Mechanism of Action Apoptosis inhibitors; Apoptotic protease activating factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hearing loss

Most Recent Events

  • 26 Sep 2017 Spiral Therapeutics receives positive feedback from the US FDA for its pre-IND submission for LPT 99
  • 26 Sep 2017 Spiral Therapeutics plans a phase I trial for Hearing loss in USA in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top